Skip to main content

Table 7 Comparison of breast cancers in patients with CHEK2 mutations to cancers in patients without CHEK2 mutations

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Feature

 

CHEK2-positive cases

CHEK2-negative cases

p

  

(n = 252)

(n = 2976)

 

Age in years (mean)

 

44.2

44.3

0.7

Age group

20–30

3.6% (9/252)

1.7% (52/2976)

0.07

 

31–40

15.9% (40/252)

17.2% (512/2976)

0.7

 

41–50

80.5% (203/252)

81% (2412/2976)

0.9

Histology

ductal G1–2 grade

29.3% (54/186)

26.9% (622/2315)

0.6

 

ductal G3 grade

10.7% (20/186)

12.7% (294/2315)

0.5

 

medullary

2.1% (4/186)

4.9% (113/2315)

0.1

 

lobular

21.5% (40/186)

15.8% (366/2315)

0.05

 

tubulo-lobular

4.3% (8/186)

3.6% (83/2315)

0.8

 

DCIS

11.3% (21/186)

7.2% (168/2315)

0.06

 

other

4.8% (9/186)

5.1% (118/2315)

1.0

 

missing or unknown

16.7% (31/186)

23.8% (551/2315)

0.03

Pre-operative chemotherapy

 

27.7% (66/238)

24.5% (661/2693)

0.3

Oestrogen receptor

positive

65.1% (97/149)

63.7% (1048/1646)

0.8

Tumour size (cm)

<1 cm

5.9% (9/152)

11.2% (193/1728)

0.05

 

1–2 cm

40.1% (61/152)

45.3% (783/1728)

0.2

 

>2 cm

53.9% (82/152)

43.5% (752/1728)

0.01

Lymph nodes

positive

45.0% (68/151)

40.1% (722/1777)

0.3

Multicentric

 

28.7% (41/143)

19.5% (316/1619)

0.01

Bilateral

 

2.3% (5/215)

3.3% (84/2531)

0.6

Family history positive*

 

13.8% (31/224)

8.9% (237/2652)

0.02

  1. *family history refers to a first-degree relative of a proband affected with breast cancer
  2. DCIS – intraductal cancer (ductal carcinoma in situ) with microinvasion; p – p-value